Neurogene Inc — Cash Flow (NASDAQ:NGNE) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities 24.57 M47.56 M45.61 M51.4 M70.6 M 77.2 M Cash from investing activities 2.22 M3.26 M59.13 M25.64 M125.26 M 118.22 M Cash from financing activities 77.14 M732 K161 K92.48 M184.07 M 187.84 M Free cash flow 22.36 M44.3 M44.5 M51.08 M69.79 M 76.03 M

Haberler

Netflix, Dell among market cap stock movers on Friday

Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE)

Neurogene hissesi FDA’nın çığır açan tedavi statüsüyle %30 yükseldi

Neurogene stock surges 30% on FDA breakthrough therapy status

FDA grants breakthrough therapy status to Neurogene’s Rett drug

Stifel, Neurogene hissesi için Al tavsiyesini yineliyor, güvenli marjı vurguluyor

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin

Neurogene doses multiple patients in Rett syndrome gene therapy trial

Citizens, Taysha Gene Therapies hissesi için Piyasa Performansı Üstü notunu yineledi

Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE)